Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 2a Study to Evaluate the Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy

NCT04042623 is registered in ClinicalTrials.gov with Aravive, Inc. as lead sponsor.

NCT NCT04042623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04042623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 2a Study to Evaluate the Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
Lead sponsor
Aravive, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
November 27, 2019
Completion date
August 1, 2020
Enrollment
1 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

iga nephropathy